Investigational drug · Phase 3
Mibavademab
Also called: REGN4461
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Lipodystrophy, Functional Hypothalamic Amenorrhea, FHA.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
8
Any phase or sponsor naming "Mibavademab"
First trial start
2024
Apr 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mibavademab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Generalized Lipodystrophy
- Functional Hypothalamic Amenorrhea
- FHA
- Monogenic Obesity
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Mibavademab" as an intervention, largest first.
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06373146 · 392 participants · Start Apr 24, 2024 · Primary completion Dec 15, 2025
Drug: Tirzepatide; Mibavademab and 2 more · For: Obesity
Sites: Gardena, California; Irvine, California; Los Angeles, California · 17 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07235917 · 34 participants (planned) · Start Mar 11, 2026 · Primary completion Jan 28, 2028
Drug: Mibavademab · For: Functional Hypothalamic Amenorrhea; FHA
Sites: Phoenix, Arizona; West Hills, California; New Haven, Connecticut · 11 sites in all
- Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07220785 · 28 participants (planned) · Start Mar 13, 2026 · Primary completion May 19, 2028
Drug: Mibavademab; Placebo · For: Generalized Lipodystrophy
Sites: Ann Arbor, Michigan; Dallas, Texas; Fortaleza, Brazil · 9 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05088460 · 20 participants · Start Feb 28, 2022 · Primary completion Dec 13, 2023
Drug: REGN4461; Matching Placebo · For: Familial Partial Lipodystrophy; Metabolic Abnormalities
Sites: Boca Raton, Florida; Bethesda, Maryland; Ann Arbor, Michigan · 8 sites in all
- Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04159415 · 16 participants · Start Jan 7, 2020 · Primary completion Jan 5, 2022
Drug: Placebo; Low-Dose REGN4461 and 1 more · For: Generalized Lipodystrophy
Sites: Bethesda, Maryland; Ann Arbor, Michigan; Dallas, Texas · 8 sites in all
- A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06548100 · 9 participants · Start Dec 16, 2024 · Primary completion Jul 9, 2026
Drug: mibavademab · For: Generalized Lipodystrophy
Sites: Bethesda, Maryland; Ann Arbor, Michigan
- A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and AdultsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07220772 · 4 participants (planned) · Start Feb 9, 2026 · Primary completion Jun 18, 2027
Drug: Mibavademab · For: Monogenic Obesity
Sites: Ulm, Germany; Esplugues de Llobregat, Spain; Ankara, Turkey (Türkiye) · 4 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT04710056
Drug: REGN4461 · For: Lipodystrophy; Generalized Lipodystrophy (GLD); Monogenic Obesity (MOB)
Newest research
PubMed records naming it or its code names, newest first.
- Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions.
Besci O, Celik Guler M, Foss-Freitas MC, et al. · Expert Rev Endocrinol Metab 2025
- Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first-in-human phase I study.
Gewitz A, Mendell J, Wang Y, et al. · Clin Transl Sci 2024
- Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency.
Altarejos JY, Pangilinan J, Podgrabinska S, et al. · Sci Transl Med 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.